Twist Bioscience Releases 2024 Corporate Responsibility Report and Quantifies Carbon Footprint of Oligo Manufacturing Process for NGS Target Enrichment Panels
“At Twist, we’re always looking to the future and improving what we do, whether that's delivering new products, providing development opportunities for our employees, continuing to hold ourselves to the highest standards of biosecurity or our efforts in sustainability,” said Emily M. Leproust, Ph.D., CEO and co-founder of
Dr. Leproust continued, “Sustainability starts with our platform. Whether our customers purchase genes and other synbio products manufactured in our Wilsonville facility or target enrichment panels manufactured in
An Inherently Sustainable Platform
Twist’s silicon-based synthetic DNA manufacturing platform offers a more sustainable alternative to legacy methods by miniaturizing the chemical reaction to synthesizing DNA, using 99.8% less reagents than 96-well plate approaches. Twist quantified the carbon footprint of manufacturing a single gene using its silicon chip-based platform compared to approaches that use a 96-well plate. Twist’s approach emits 36 grams (0.036 kilograms) of carbon dioxide equivalent (CO2e) per gene, compared to up to 23,000 grams (23 kilograms) per gene emitted by 96-well plate approaches2.
Beyond quantifying the carbon footprint of manufacturing a single gene, Twist calculated the carbon footprint of its oligo manufacturing process specific to its NGS target enrichment panels and found that the chemicals used in Twist's NGS target enrichment panel production for fiscal 2023 generated 180,000 kg of CO2e emissions. In contrast, using the industry standard 96-well plate chemical volumes and approach to manufacture the equivalent number of NGS target enrichment panels would have generated a massive 470,000,000 kg of CO2e2.
For the first time in its 11-year history, Twist disclosed its Scope 1 and Scope 2 emissions of 6.27 and 14,315 metric tons of CO2e, respectively, across its
Commitment to Ethics and Governance
Twist works with governments as well as other DNA synthesis providers to develop, promote and evolve a consistent set of biosecurity best practices. These partnerships align with the company's dedication to biosecurity and export control screening, ensuring Twist supports safe, responsible research and that potentially dangerous DNA sequences are not synthesized or shipped to unlicensed organizations.
Twist also prioritizes the privacy of its customers and employees by consistently evaluating and upgrading its system security. The company has implemented robust cybersecurity and biosecurity policies, including an
Fostering a Diverse Workforce
Twist is committed to employing a diverse workforce and fostering a culture of inclusivity. As of the end of fiscal 2023, 56% of Twist’s
Twist’s commitment to diversity in its recruitment efforts extends to partnerships with local community colleges in
As part of its commitment to employee development, Twist encourages educational and developmental growth for employees by offering a year-long leadership program for mid-level managers and an annual tuition reimbursement of up to
In fiscal 2023, Twist employees volunteered a total of 1,143 hours to numerous causes and organizations, made possible by a Volunteer Time Off program encouraging employees to participate in philanthropic initiatives by providing 8 hours of paid time off per year for volunteer efforts.
To download the full report visit: https://www.twistbioscience.com/company/corporate-responsibility
1Calculated Twist internal data using
2Calculated Twist internal data using
About
Follow us on LinkedIn | X | YouTube | Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the execution of Twist’s vision and strategy with respect to sustainability, diversity, governance, and ethical commitments and the completion of Twist’s projects that are currently underway, in development or otherwise under consideration. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909630223/en/
For Investors:
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com
For Media:
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com
Source: